1 Introduction Cancer persists as the second leading cause of global mortality, with epidemiological projections estimating 19.97 million new cases and 9.74 million deaths in 2024 ( Nutraceuticals have emerged as compelling candidates in translational oncology, leveraging their dual capacity to potentiate anticancer effects while mitigating treatment-related toxicity ( 2 O 2 )-mediated responses, including adenosine triphosphate (ATP) depletion, iron-regulated epigenetic reprogramming, anti-apoptotic protein B cell lymphoma 2 (Bcl-2) inhibition, Bax (Bcl-2 associated X protein, a well-known pro-apoptotic mediator) activation, mitochondrial hyperpolarization induction, the cleavage of poly (ADP-ribose) polymerase (PARP, a known apoptotic indicator) and caspases, mainly caspases 3 and 7 as well as targeting hypoxia-inducible factor-1 ( HIF- ) ( The therapeutic application of VC in oncology has been plagued by persistent controversies, particularly regarding dose-response relationships and administration route efficacy

Platelet-Rich Plasma (PRP) & Stem Cells
Oliver, R
Hamadneh L, Bahader M, Abuarqoub R, AlWahsh M, Alhusban A, Hikmat S
Its tempting to rub it to soothe the discomfort, but resist the urge
Reduced mitochondrial number and their increased deformation may damage the normal oxidative decomposition of fat, thereby increasing hepatic fat content